Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Retatrutide Phase 2 Obesity Trial: Efficacy and Safety at 48 Weeks New England Journal of Medicine Phase 2 trial in 338 adults with obesity showed retatrutide 12 mg produced 24.2% body weight loss at 48 weeks the highest reported for any anti-obesity pharmacotherapy with manageable GI side effects
His doctor told him about the injectable ahead of its release in May 2022, and he's been taking it ever since
Giorgos Bakoyannis, PhD, adjunct associate professor of biostatistics and health data science, was a co-author on the study
Smaller trials and integrative-medicine practitioner reports have suggested possible benefits on insulin sensitivity and ovulation induction, but the trial body has not reached the scale and consistency that, say, inositol at the 40:1 ratio has accumulated
Free radical damage can interfere with the body's ability to produce new collagen effectively
These are benefits that surgery cant achieve
